



## Evaluation of Vaccine Efficacy, Safety and Immunogenicity against Influenza and COVID-19

Guest Editor:

**Dr. Roland Zahn**

Janssen Prevention Center, 2333  
CN Leiden, The Netherlands

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editor

Prophylactic vaccines against influenza and COVID-19 have been given to billions of individuals and are effective for the prevention of severe disease. While the safety and efficacy of current influenza vaccines are established based on decades of use, new vaccine concepts to achieve higher efficacy and preferentially more universal protection have a yet to be defined immunogenicity, safety and efficacy profile. Some of these new vaccine concepts have been used for the rapidly developed and licensed COVID-19 vaccines. These have shown to be safe with a high efficacy against severe disease; however, safety concerns of rare cases of myocarditis and vaccine-induced immune thrombotic thrombocytopenia (VITT) shortly after vaccination became apparent, requiring further research to understand their etiology. SARS-CoV-2 vaccines have shown in part waning immunity and reduced efficacy against variants of concern, requiring the development of strategies to improve and further develop these new vaccine concepts and explore new ones.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)